Impact of Fibroblast Growth Factor 23 (FGF-23) and Serum Phosphate on Allograft Function and Mortality in Kidney Allograft Recipients
This trial is active, not recruiting.
|Start date||May 2009|
|End date||January 2015|
|Trial size||200 participants|
|Trial identifier||NCT00903578, KT-1|
The present study will examine whether serum FGF-23 and serum phosphate at baseline of kidney transplant recipients can predict progression of allograft dysfunction at 3 years and all-cause mortality at 5 years.
Progression of allograft dysfunction and all-cause Mortality
time frame: 3 and 5 years
Relationship of FGF-23 and 25-OH-D, 1-25-OH-D, PTH, calcium, phosphate, urine phosphate and eGFR
time frame: 1 year
Male or female participants at least 18 years old.
- at least one year post-transplantation
- no more than 10% increase in serum creatinine for the past 3 months
- refuse to participate in the study
- any acute illnesses
|Official title||Impact of FGF-23 and Serum Phosphate on Allograft Function and Mortality in Kidney Allograft Recipients|
|Principal investigator||Sinee Disthabanchong, M.D.|
Call for more information